What Is Tesamorelin? Mechanism and Evidence

TL;DR: Tesamorelin (brand name Egrifta; also designated TH9507) is a stabilized synthetic analog of endogenous growth hormone-releasing hormone (GHRH). Unlike most GHRH analogs studied in research contexts, tesamorelin is an FDA-approved prescription medication, indicated specifically for the reduction of excess visceral abdominal fat in HIV-infected adults with HIV-associated lipodystrophy. Phase-3 clinical trial evidence (n>800) documents ~15–18% visceral adipose tissue (VAT) reduction at 26 weeks. Its mechanism operates via GHRH receptor agonism → pulsatile GH secretion → IGF-1 axis activation. It is a prescription-only medicine; this article is educational mechanism and evidence science only.

Important Compliance Note: This article is for educational and research reference purposes only. Tesamorelin (Egrifta) is an FDA-approved prescription medication indicated for one specific condition: reduction of excess visceral abdominal fat in HIV-infected adults with HIV-associated lipodystrophy. This content does not provide medical advice, does not describe how to obtain or use this medication, does not address off-label use, and does not constitute a dosing protocol. Only a licensed physician can prescribe tesamorelin and assess its appropriateness for any individual. For adults 21+ with a research interest only.

What Is Tesamorelin? Definition and Classification

Tesamorelin is a synthetic analog of human growth hormone-releasing hormone (GHRH), the hypothalamic peptide that signals the anterior pituitary to release growth hormone (GH). Its full chemical designation is trans-3-hexenoic acid-GHRH(1-44)-NH₂, sometimes written as TH9507. Whereas native GHRH(1-44) degrades rapidly in plasma, with a half-life measured in minutes, tesamorelin incorporates a trans-3-hexenoic acid modification at the N-terminus that confers resistance to dipeptidyl peptidase-4 (DPP-4) cleavage, extending its biological activity.

Tesamorelin is marketed under the brand name Egrifta (and subsequently Egrifta SV, a more concentrated formulation) by Theratechnologies Inc. It holds FDA approval granted in November 2010 for a single, specific indication: reduction of excess visceral abdominal fat in HIV-infected adults with lipodystrophy. This is a narrowly defined regulatory approval, it does not extend to general body composition, anti-aging, athletic performance, or any other indication.

How Does Tesamorelin Work? The GHRH Receptor Mechanism

What is the GHRH receptor pathway?

Tesamorelin exerts its primary biological effect by binding and activating the GHRH receptor (GHRHR) expressed on somatotroph cells of the anterior pituitary gland. GHRHR is a G-protein–coupled receptor; agonist binding triggers adenylyl cyclase activation, cyclic AMP accumulation, and downstream protein kinase A signaling that culminates in the synthesis and pulsatile secretion of growth hormone (GH) from somatotrophs.

Critically, tesamorelin stimulates pulsatile GH secretion, preserving the physiological rhythm of GH release, rather than producing the sustained, non-pulsatile GH elevations associated with exogenous recombinant human GH (rhGH) injection. This distinction is pharmacologically important: pulsatile GH patterns are associated with differential tissue effects compared to continuous GH exposure, including more selective lipolytic activity in visceral adipose tissue.

How does GH activation lead to visceral fat reduction?

Growth hormone stimulates lipolysis (the breakdown of stored triglycerides) in adipose tissue via hormone-sensitive lipase (HSL) activation. Visceral adipose tissue (VAT), the metabolically active fat depot surrounding abdominal organs, is particularly responsive to GH-mediated lipolysis due to its high density of GH receptors and active lipid turnover compared to subcutaneous adipose tissue. Tesamorelin’s GH-stimulating mechanism therefore has a preferential effect on VAT reduction.

GH secretion additionally drives hepatic and peripheral production of insulin-like growth factor 1 (IGF-1). In the phase-3 clinical trials reviewed below, tesamorelin treatment produced a mean IGF-1 increase of approximately 81–108% versus baseline, consistent with robust GH axis activation. IGF-1 elevation is a standard pharmacodynamic marker used to confirm GHRH analog activity in clinical studies.

Why does tesamorelin spare subcutaneous fat?

A consistent finding across tesamorelin’s clinical trial program is that VAT decreases significantly while subcutaneous adipose tissue (SAT) does not decrease, and in some analyses shows no statistically significant change. The mechanistic basis appears to relate to depot-specific differences in adrenergic receptor density, GH receptor expression, and the relative rate of lipolytic responsiveness. The clinical implication is that tesamorelin’s effects are selectively targeted to the abdominal visceral compartment, which is the therapeutically relevant depot in HIV-associated lipodystrophy.

What Is HIV-Associated Lipodystrophy? The Clinical Context

HIV-associated lipodystrophy is a metabolic complication documented in HIV-infected individuals receiving antiretroviral therapy (ART), particularly older protease-inhibitor–based regimens. It is characterized by disproportionate visceral fat accumulation in the abdomen, sometimes accompanied by peripheral fat wasting (lipoatrophy) from the face, limbs, and buttocks. The condition is associated with an unfavorable cardiometabolic risk profile, elevated triglycerides, dyslipidemia, and insulin resistance, and significant patient-reported body image distress.

Prior to tesamorelin’s approval, treatment options for the visceral fat component were limited. Recombinant human GH (rhGH) could reduce VAT but was associated with insulin resistance, arthralgias, edema, and other adverse effects at the doses required. Tesamorelin’s GHRH mechanism, which works through the body’s own pituitary-regulated GH pulse architecture, was hypothesized to produce targeted VAT reduction with a more favorable safety profile, a hypothesis the phase-3 trial program addressed directly.

What Does the Phase-3 Clinical Trial Evidence Show?

The landmark NEJM trial: Falutz et al. 2007

The foundational tesamorelin trial enrolled 412 HIV-infected patients with excess abdominal fat accumulation in a multicenter, randomized, double-blind, placebo-controlled design. Patients received either subcutaneous tesamorelin 2 mg/day or placebo for 26 weeks. The primary endpoint was percent change in visceral adipose tissue by CT scan. According to PubMed, the results published by Falutz et al. in The New England Journal of Medicine (2007; PMID 18057338) showed:

• VAT decreased by 15.2% in the tesamorelin group versus an increase of 5.0% in the placebo group (P<0.001)
• Triglycerides decreased by 50 mg/dL (tesamorelin) versus increased by 9 mg/dL (placebo) (P<0.001)
• Total cholesterol-to-HDL ratio improved significantly in the treatment group (P<0.001)
• IGF-1 levels increased by 81.0% (tesamorelin) vs. decreased by 5.0% (placebo) (P<0.001)
• No significant differences in glycemic measures were observed between groups

This study constitutes the primary evidence anchor for tesamorelin’s FDA-approval dossier and remains the most-cited tesamorelin publication in the peer-reviewed literature.

The 12-month randomized trial: Falutz et al. 2010 (JAIDS)

A 12-month study of 404 HIV-infected patients with excess abdominal fat examined both efficacy and durability of effect. Based on articles retrieved from PubMed, Falutz et al. in Journal of Acquired Immune Deficiency Syndromes (2010; PMID 20101189) reported:

• VAT decreased by -10.9% (-21 cm²) in the tesamorelin group versus -0.6% (-1 cm²) in placebo at 6 months (P<0.0001)
• Patients continuing tesamorelin through 12 months achieved approximately 18% total VAT reduction (P<0.001)
• Trunk fat, waist circumference, and waist-hip ratio all improved significantly with no change in limb or abdominal SC fat
• VAT reaccumulated rapidly in patients who switched from tesamorelin to placebo at month 6, indicating the effect is dependent on continued treatment
• No significant changes in glucose parameters; drug was well tolerated

The pooled phase-3 analysis: Falutz et al. 2010 (JCEM)

To provide greater statistical power, data from two multicenter phase-3 trials were pooled in an analysis of 806 ART-treated HIV patients randomized 2:1 to tesamorelin 2 mg/day or placebo. According to PubMed, Falutz et al. in The Journal of Clinical Endocrinology and Metabolism (2010; PMID 20554713) documented:

• At week 26: VAT decreased significantly in tesamorelin-treated patients (-24 ± 41 cm²) versus placebo (+2 ± 35 cm²) (P<0.001; treatment effect -15.4%)
• No significant change in abdominal subcutaneous adipose tissue (treatment effect -0.6%)
• Triglycerides: -37 ± 139 mg/dL (tesamorelin) versus +6 ± 112 mg/dL (placebo) (P<0.001)
• Cholesterol-to-HDL ratio treatment effect: -7.2% (P<0.001)
• At week 52 in the continuous-treatment group: VAT reduction maintained at -17.5% with preserved lipid improvements
• Significant improvements in patient- and physician-rated belly appearance scores (P<0.001 to 0.002)

Long-term safety extension: Falutz et al. 2008 (AIDS)

A 26-week safety extension phase evaluated tolerability and durability of effect through 52 total weeks. Based on articles retrieved from PubMed, Falutz et al. in AIDS (2008; PMID 18690162) confirmed that VAT reduction was sustained at approximately -18% at 52 weeks in those who continued tesamorelin treatment, while patients who discontinued experienced VAT reaccumulation. Glucose parameters remained non-significantly changed through 52 weeks. Adverse event prevalence during the extension was comparable to the initial phase, supporting a consistent safety profile over one year of treatment.

Metabolic responder analysis: Stanley et al. 2012 (Clinical Infectious Diseases)

A per-protocol analysis of 402 subjects from the phase-3 program stratified patients as tesamorelin “responders” (≥8% VAT reduction) or “non-responders” to assess whether VAT reduction itself drove metabolic improvement. According to PubMed, Stanley, Falutz et al. in Clinical Infectious Diseases (2012; PMID 22495074) found that responders experienced significantly greater triglyceride reduction, better preservation of glucose homeostasis (attenuated fasting glucose and HbA1c rise), and improved adiponectin levels compared to non-responders, suggesting the metabolic benefits are mechanistically linked to the degree of VAT reduction, not merely to tesamorelin exposure per se.

Summary of Tesamorelin’s Evidence Profile

How Does Tesamorelin Compare to Other GHRH Analogs?

Tesamorelin shares its fundamental mechanism, GHRH receptor agonism driving pulsatile pituitary GH secretion, with sermorelin (GHRH[1-29]) and CJC-1295 (a DAC-modified GHRH analog), both of which are studied as research compounds. The critical distinction is regulatory status:

• Tesamorelin (Egrifta): FDA-approved prescription drug; one specific indication; extensive phase-3 RCT evidence base; requires physician prescription
• Sermorelin: Research compound; no current FDA-approved indication; studied in preclinical and limited clinical contexts
• CJC-1295: Research compound; no FDA-approved indication; studied in early-phase clinical and preclinical contexts

Structurally, tesamorelin’s trans-3-hexenoic acid modification (yielding TH9507) extends plasma half-life by protecting the N-terminal Tyr-Ala bond from DPP-4 cleavage, a common degradation mechanism for native GHRH. This stabilization strategy is distinct from the drug-affinity complex (DAC) technology used in CJC-1295.

What Is Tesamorelin’s Prescription and Regulatory Status?

FDA (United States)

Tesamorelin received FDA approval in November 2010 as a prescription-only medication under the brand name Egrifta (Theratechnologies Inc.). An updated formulation, Egrifta SV (2 mg/mL concentrated solution), was subsequently approved. The approved indication is specifically: “reduction of excess abdominal fat in HIV-infected patients with lipodystrophy.” Tesamorelin is regulated as a new molecular entity under 21 CFR. It is not available over the counter and is not a dietary supplement ingredient. All prescribing, dispensing, and use must occur within the bounds of FDA-approved labeling and applicable state pharmacy law.

International and Other Regulatory Contexts

Tesamorelin’s regulatory status outside the United States varies by jurisdiction. Researchers and clinicians in other countries should consult relevant national regulatory agencies for current approval status. The compound has been reviewed by Health Canada and other bodies in the context of HIV-associated lipodystrophy.

Frequently Asked Questions About Tesamorelin

Is tesamorelin FDA approved?

Yes, tesamorelin (brand name Egrifta) is FDA approved as a prescription medication for a specific indication: reduction of excess visceral abdominal fat in HIV-infected adults with HIV-associated lipodystrophy. This approval does not extend to other uses. It is a prescription drug requiring physician authorization; it cannot be legally obtained or used for other purposes under FDA-approved labeling.

How does tesamorelin work?

Tesamorelin is a stabilized synthetic GHRH analog that binds and activates GHRH receptors on anterior pituitary somatotrophs, stimulating pulsatile growth hormone secretion. The resulting GH elevation drives IGF-1 production and promotes preferential lipolysis in visceral adipose tissue, the mechanism underlying its clinically documented VAT reduction in HIV-associated lipodystrophy.

What did the tesamorelin phase-3 clinical trials show?

Two multicenter, double-blind, placebo-controlled phase-3 trials (pooled n=806), primarily led by Falutz et al. and published in the NEJM and JCEM, demonstrated approximately 15–18% visceral adipose tissue reduction at 26 weeks with daily subcutaneous tesamorelin 2 mg versus placebo (P<0.001). The effect was maintained at 52 weeks with continued treatment and reversed upon discontinuation. Triglycerides and cholesterol-to-HDL ratio also improved significantly, with no clinically meaningful changes in glucose parameters.

What is the difference between tesamorelin and sermorelin or CJC-1295?

All three are GHRH analogs activating pituitary GH secretion. Tesamorelin is the only one among them that is FDA approved as a prescription drug, for HIV-associated lipodystrophy only. Sermorelin and CJC-1295 are research compounds with no FDA-approved therapeutic indication. Tesamorelin’s TH9507 modification confers DPP-4 resistance and extended activity compared to native GHRH(1-44), which is distinct from the DAC technology used in CJC-1295.

Prescription medicine, research reference only. Tesamorelin (Egrifta) is an FDA-approved prescription medication for HIV-associated lipodystrophy; it is not available without a physician’s prescription. This article is for educational and research reference purposes only and does not constitute medical advice, does not describe off-label uses or dosing, and does not recommend human use of any compound outside its FDA-approved indication. Nothing here is intended to diagnose, treat, cure, or prevent any disease. All clinical findings referenced are sourced from published peer-reviewed literature and FDA labeling, read primary sources in full. According to PubMed, the primary citations are: Falutz et al., NEJM 2007 (DOI); Falutz et al., AIDS 2008 (DOI); Falutz et al., JAIDS 2010 (DOI); Falutz et al., JCEM 2010 (DOI); Stanley & Falutz et al., Clin Infect Dis 2012 (DOI). Consult a licensed physician for any personal health decisions. Must be 21+.